• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Immunotherapy Improves Five-year Survival Rate of People with Advanced Lung Cancer

In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15 percent of people with advanced non-small cell lung cancer live for at least five years — and 25 percent of patients whose tumor cells had a specific protein lived at least that long. When the study began in 2012, the average five-year survival rate was just 5.5 percent for people with that type of cancer.

Immunotherapy Infographic.png

Immune-mediated adverse events at three years (September 6, 2016) and at five years (November 5, 2018) of follow-up. Immune-mediated adverse events were classified based on a list of preferred terms identified by the sponsor as having an immune etiology. Because there were changes in events included in this list between the three- and five-year analyses, certain events classified as immune-mediated at three years may not have been so-classified at five years.
Graphic: Courtesy of Dr. Edward Garon

 

The study, conducted by researchers at the UCLA Jonsson Comprehensive Cancer Center and more than 30 other centers, was the first to evaluate pembrolizumab as a treatment for lung cancer. “We can no longer look at this disease as one in which we should always be measuring survival in months,” says Edward Garon, MD (FEL ’06), associate professor of medicine and a member of the Jonsson Cancer Center. “These findings substantially alter the outlook for people with advanced non-small cell lung cancer. The fact that we have patients in this trial who are still alive, and thriving, seven years after starting pembrolizumab is quite remarkable.”

The study involved 550 participants, 101 of whom had not received any previous treatments for advanced cancer and 449 who had. All participants were given pembrolizumab every two-to-three weeks. In 2015, just three years into the study, the participants’ positive early responses to pembrolizumab prompted the Food and Drug Administration to approve the treatment for some people with non-small cell lung cancer. Since then, the drug has been approved for broader use, becoming a staple for managing the disease.

Pembrolizumab is an immune checkpoint inhibitor that works by blocking the interaction between PD-1 and PD-L1, which are both proteins on the surface of T cells. By blocking this interaction, which generally inhibits the body’s immune response, pembrolizumab activates the immune system to better attack the cancer. The researchers found that the drug worked better in people who had higher levels of PD-L1, regardless of whether they had been previously treated for cancer.

Among those who were previously untreated, 29.6 percent of those with PD-L1 expression in at least half of their tumor cells were alive after five years, versus 15.7 percent of those with low PD-L1 expression. For people who had received prior cancer treatment, 25 percent who had PD-L1 expression in at least half of their tumor cells were alive after five years, while 12.6 percent of those with low PD-L1 levels and 3.5 percent with no PD-L1 expression lived that long.

According to the National Cancer Institute, lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. Only about one-third of patients see substantial tumor shrinkage with standard chemotherapy, and people with the disease survive for an average of just a year after they are diagnosed. More than 228,000 people this year will be diagnosed with the disease in the U.S., and the American Cancer Society estimates that nearly 143,000 will die of lung cancer in 2019.

— Denise Heady

“Five-Year Overall Survival for Patients with Advanced Non?small-cell Lung Cancer Treated with Pembrolizumab: Results from the Phase I KEYNOTE-001 Study,” Journal of Clinical Oncology, June 2, 2019


Previous
Antibiotics before Liver Transplants Leads to Better Results
Next
Research Explains How Eyes See Continuously in Bright Light


YOU ARE VIEWING

Fall 2019

Fall 2019
Printable PDF
IN THIS ISSUE
  • Unlocking the Unknown: The Power and Promise of Collaboration
  • Students Travel to a Remote Peruvian City to Learn about Medicine with Limited Resources
  • The Brains of Pairs of Animals Synchronize during Social Interaction
  • More HPV Vaccinations could Prevent Cancer in 1,300 Californians
  • Antibiotics before Liver Transplants Leads to Better Results
  • Immunotherapy Improves Five-year Survival Rate of People with Advanced Lung Cancer
  • Research Explains How Eyes See Continuously in Bright Light
  • Three-drug Combination Helps Curb the Growth of Deadly Type of a Cancer
  • Peptides that Mimic ‘Good Cholesterol’ Reverse Inflammatory Bowel Disease in Mice
  • Giving Where the Rubber Meets the Road
  • The Accidental Scientist
  • Answers, At Last
  • Coal Miner’s Son
  • A Day in the Life: Child Life Specialists in the Operating Room
  • Journey of a Lifetime
  • Awards & Honors
  • In Memoriam
  • Sold-out Wonder of Women Summit Celebrates Whole Health
  • UCLA Receives $10 million from The Eli and Edythe Broad Foundation to Support Stem Cell Research
  • Taste for a Cure Raises Money for Cancer Research
  • Cyclists Help Tour de Pier Surpass Fundraising Target
  • UCLA Jonsson Comprehensive Cancer Center Names New Research Suite
  • Semel Insitute Introduces 2018-19 Max Gray Fellows
  • UCLA Women’s Cardiovascular Center Hosts a Community Update on Women’s Heart Health
  • Vision Specialists Establish Smotrich Family Optometric Clinician-Scientist Chair
  • UCLA Stein Eye Institute Celebrates the Bert O. Levy Chair
  • Innovations in Nutrition and Mindfulness on the Road to Health and Wellness
  • Two Young Friends Launch Toy Drive to Benefit Mattel Patients
  • Gifts
  • In Memoriam
  • Thanks to the Ants
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth